Your browser does not allow saving data (e.g. private mode): bookmarks will be lost when the tab closes.
Search PubMed
Keywords, author, journal, years — results from PubMed, abstracts with Russian translation, bookmarks in your browser.
Found: 26 075
Page 54 of 1000-
CRISPR/Cas9 Immune System as a Tool for Genome Engineering.
CRISPR/Cas (clustered regularly interspaced short palindromic repeats/CRISPR-associated) adaptive immune systems constitute a bacterial defence against invading nucleic acids derived from bacteriophages or plasmids. This prokaryotic system was adapted in molecular biology and became one of the most powerful and versatile platforms for genome engineering. CRISPR/Cas9 is a simple and rapid tool which enables the efficient modification of endogenous genes in various species and cell types. Moreover, a modified version of the CRISPR/Cas9 system with transcriptional repressors or activators allows robust transcription repression or activation of target genes. The simplicity of CRISPR/Cas9 has resulted in the widespread use of this technology in many fields, including basic research, biotechnology and biomedicine.
-
Local magnetic activation of CRISPR.
-
CRISPR treatment inserted directly into the body for first time.
-
Caribou's first CRISPR CAR-T impresses.
-
The Patent Landscape for CRISPR Genome Editing in Australia.
Although Australia has a proud record of health and medical research, it finds less traction when it comes to innovative product development. Patent filings are recognised as one of the measures of national innovation, and this is one measure where Australian innovators are falling short. We examined whether there may be discrete pockets of innovation in particular areas of technology where Australian researchers are making significant contributions. This study used patent filings as a measure of innovation and used clustered regularly interspaced short palindromic repeat (CRISPR) genome editing as a case study. We found a rich patent landscape, with filings for general methods and compositions and for specific diseases. However, the contribution by Australian applicants was small, with only four out of 519 filings. This indicates that navigating the CRISPR patent landscape to secure freedom to operate is likely to be complex for Australian innovators in this field.
-
A CRISPR Landing for Genome Rewriting at Locus-Scale.
-
CRISPR-anti-CRISPR dynamics: evolutionary, ecological and biotechnological perspectives.
Phages and bacteria are engaged in an evolutionary arms race. CRISPR-Cas systems allow bacteria to resist phage predation, contributing to competitive advantages for certain bacterial strains. However, phages generate a diverse anti-CRISPR (Acr) proteins to effectively neutralise the CRISPR-Cas system. Acr proteins restore phage infectivity, which may contribute in limiting the dominance of CRISPR-armed bacterial strains, potentially influencing the microbial diversity in certain environments. Acrs can influence microbial community dynamics which may indirectly affect ecosystem functions such as nutrient cycling in certain marine and soil ecosystems. The potential of these Acrs proteins in controlled and reversible genome editing, highlights their potential as regulatory components for genome editing systems. This review discusses the molecular mechanism of CRISPR and anti-CRISPRs, highlights the diversity and limitations of known inhibitory mechanisms, ecological role of anti-CRISPRs and highlights their expanding application in microbial evolution and biotechnology.
-
Advancing biotechnology with CRISPR/Cas9: recent applications and patent landscape.
Clustered regularly interspaced short palindromic repeats (CRISPR) is poised to become one of the key scientific discoveries of the twenty-first century. Originating from prokaryotic and archaeal immune systems to counter phage invasions, CRISPR-based applications have been tailored for manipulating a broad range of living organisms. From the different elucidated types of CRISPR mechanisms, the type II system adapted from Streptococcus pyogenes has been the most exploited as a tool for genome engineering and gene regulation. In this review, we describe the different applications of CRISPR/Cas9 technology in the industrial biotechnology field. Next, we detail the current status of the patent landscape, highlighting its exploitation through different companies, and conclude with future perspectives of this technology.
-
Targeted RNA m6A Editing Using Engineered CRISPR-Cas9 Conjugates.
N6-methyladenosine (m6A) is a major epitranscriptomic mark exerting crucial diverse roles in RNA metabolisms, including RNA stability, mRNA translation, and RNA structural rearrangement. m6A modifications at different RNA regions may have distinct molecular effects. Here, we describe a CRISPR-Cas9-based approach that enables targeted m6A addition or removal on endogenous RNA molecules without altering the nucleotide sequence. By fusing a catalytically inactive Cas9 with engineered m6A modification enzymes, the programmable m6A editors are capable of achieving RNA methylation and demethylation at desired sites, facilitating dissection of regional effects of m6A and diversifying the toolkits for RNA manipulation.
-
CRISPR: Beyond the Excitement.
PubMed returns only the first 10,000 results — refine the query to see the rest.